Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 17, Issue 8, Pages 2212-2214Publisher
WILEY
DOI: 10.1111/ajt.14263
Keywords
-
Categories
Ask authors/readers for more resources
Fetal hemoglobin induction is a key point in the management of sickle cell disease (SCD). We report the case of a kidney transplant recipient with SCD who was treated with everolimus, a mammalian target of rapamycin inhibitor. At 10 months after initiating therapy, the patient's fetal hemoglobin level was dramatically increased (from 4.8% to 15%) and there was excellent tolerance to treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available